BioCentury
ARTICLE | Clinical News

ReoPro abciximab: Phase II data; Phase III; marketed as an adjunct in angioplasty

November 15, 1999 8:00 AM UTC

Final data from the company's 1,187-patient TIMI 14 trial showed a 57 percent increase in patients achieving normal flow (TIMI 3 grade) in the blocked artery 90 minutes after treatment with ReoPro plus a reduced dose of either Centocor's Retavase reteplase tPA or Genentech Inc.'s Activase alteplase tPA compared to treatment with a full dose of either of the two thrombolytics alone. Complete myocardial perfusion also was seen in 58 percent of patients receiving ReoPro combination therapy compared to 40 percent of patients receiving only thrombolytic therapy. ...